| mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
6e-06 |
| mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
4e-05 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
6e-05 |
| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
7e-05 |
| mRNA |
Axitinib |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
7e-05 |
| mRNA |
Rapamycin |
gCSI |
pan-cancer |
AAC |
-0.25 |
8e-05 |
| mRNA |
ML162 |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.0001 |
| mRNA |
PX-12 |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0001 |
| mRNA |
BRD-K34222889 |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0002 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.0002 |